A Phase 1/2 interventional study of Placebo and SRP-4053 in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 5 sites in 4 countries. Open to male participants aged 6 Years to 15 Years. Per ClinicalTrials.gov, last updated 2020-10-19.
Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 11th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2015, is one of 5 in phase 1/2, and was the 6th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 2+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States, Belgium, Germany and 6 more countries
Men only
Sarepta Therapeutics, Inc. · Sites in United States
Men only
By country, each count listing its studies:
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 6 Years to 15 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 7 · Phase 4 1
First in 2009; this study’s year is marked. 3 started in 2015.
This study's enrollment of 39 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 24 across the 25 interventional studies, 400 across the 2 observational. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
2 of the studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT07542314Sarepta Therapeutics, Inc.Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human, multiple-dose 2-part study to assess the safety, tolerability, efficacy, and pharmacokinetics of SRP-4053 in Duchenne muscular dystrophy (DMD) patients with deletions amenable to exon 53 skipping.
Part 1: Randomized, placebo-controlled dose-titration to assess safety, tolerability and pharmacokinetics of 4 dose levels of SRP-4053 in genotypically-confirmed DMD patients with deletions amenable to exon 53 skipping.
Part 2: Open-label evaluation of SRP-4053 in patients from Part 1, along with newly enrolled DMD patients with deletions amenable to exon 53 skipping and an untreated group of DMD patients with deletions not amenable to exon 53 skipping.
Safety, including adverse event monitoring and routine laboratory assessments, will be followed on an ongoing basis for all patients.
Clinical efficacy, including functional tests such as the six-minute walk test (6MWT), will be assessed at regularly scheduled study visits. Patients in the treated groups will undergo one baseline and one follow-up muscle biopsy. Patients in the untreated group will not undergo biopsies and will follow an abbreviated schedule of study assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive SRP-4053 (golodirsen) intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
Drug: SRP-4053
Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
Drug: Placebo
All eligible patients from Part 1, as well as new patients, will receive SRP-4053 (golodirsen) 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.
Drug: SRP-4053
Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic \[PK\] sampling and muscle biopsies), but at a reduced schedule through Week 144. The untreated patients are not considered as control group.
SRP-4053 placebo-matching solution for IV infusion.
SRP-4053 (golodirsen) solution for IV infusion.
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Discontinuation
Adverse event (AE) was any untoward medical occurrence in a clinical trial participant, which does not necessarily have a causal relationship with the investigational drug. A Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; Required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs that were reported or worsened on or after the start of study drug dosing through 12 weeks. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to Week 12
Part 1: Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEs
Laboratory parameters included hematology, serum chemistry (SC), urinalysis and coagulation. Number of participants with at least one potentially clinically significant abnormal finding were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potentially clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
Time frame: Baseline up to Week 12
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs
Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potential clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
Time frame: Baseline up to Week 12
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Physical Examinations
Physical examinations were performed by the Investigator, or qualified study staff. A full physical examination included a review of general appearance, head, eyes, ears, nose and throat, heart, lungs, abdomen, extremities, skin, lymph nodes, musculoskeletal, and neurological systems. Number of participants with potentially clinically significant abnormalities in physical examinations were reported. Potentially clinically significant abnormalities in physical examinations were based on Investigator's discretion.
Time frame: Baseline up to Week 12
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs
Twelve-lead ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECG reported as TEAEs presented here. The Investigator determined whether abnormal assessment results were potentially clinically significant or not.
Time frame: Baseline up to Week 12
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)
Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. Cardiac function events included cardiomegaly, tachycardia, and dyspnoea. The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECHO were reported.
Time frame: Baseline up to Week 12
Part 2a: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Total Golodirsen Group
6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 144 in total golodirsen group was reported.
Time frame: Baseline and Week 144
Part 2b: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Untreated Group (Non-exon 53 Amenable Participants)
6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 144 in untreated group (non-exon 53 amenable participants) was calculated.
Time frame: Baseline and Week 144
Part 2a: Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 48 in Total Golodirsen Group
Change from baseline in dystrophin protein levels (in muscle biopsy samples) was determined by Western blot in total golodirsen group.
Time frame: Baseline, Week 48
Part 1: Maximum Plasma Concentration (Cmax) of Golodirsen
Maximum Concentration (Cmax) of golodirsen in plasma was evaluated.
Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Part 1: Time to Reach Maximum Plasma Concentration (Tmax) of Golodirsen
Time to reach maximum plasma concentration (Tmax) of golodirsen was evaluated.
Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Part 1: Area Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Golodirsen in Plasma
Area under the concentration-time curve from time zero extrapolated to the infinity was evaluated.
Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Part 1: Apparent Volume of Distribution at Steady State (Vss) of Golodirsen
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution at steady state of golodirsen was evaluated.
Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Part 1: Elimination Half-life (T1/2) of Golodirsen
T1/2 is the time measured for the plasma concentration of drug to decrease by one half. T1/2 of golodirsen was evaluated.
Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Part 1: Total Clearance (CL) of Golodirsen
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Part 1: Mean Residence Time (MRT) of Golodirsen
MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method. Mean residence time of golodirsen was evaluated.
Time frame: Pre-dose, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16 and 24 hours post-dose at Weeks 1 (for 4 mg/kg arm), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm) and 7 (for 30 mg/kg arm)
Part 1: Renal Clearance (CLR) of Golodirsen
Renal clearance was calculated using the partial AUC0-24 from the non-compartmental analysis in plasma and AE0-24. AUC0-24 was defined as area under the plasma concentration-time curve, from time 0 to 24 hours after completion of dosing. AE0-24 was defined as total cumulative amount excreted from 0 to 24 hours. Summarized data of all urine collection intervals are reported.
Time frame: 0 to 1440 min after initiation of dosing on Day 1
Part 2a: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Total Golodirsen Group
FVC was the total amount of air exhaled during the forced expiratory volume test that was measured during spirometry and the most important measurement of lung function. This test required participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which was used to dilate participant bronchial (breathing) tubes. Percent of predicted FVC = (observed value)/ (predicted value) \* 100%.
Time frame: Baseline, Week 144
Part 2b: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Untreated Group (Non-exon 53 Amenable Participants)
FVC was the total amount of air exhaled during the forced expiratory volume test that was measured during spirometry and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which was used to dilate participant bronchial (breathing) tubes. Percent of predicted FVC = (observed value)/ (predicted value) \* 100%.
Time frame: Baseline, Week 144
Part 2a: Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group
Change from baseline in dystrophin Intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry in total golodirsen group.
Time frame: Baseline, Week 48
Part 2a: Percent Change From Baseline in Exon 53 Skipping Determined by Reverse Transcription Polymerase Chain Reaction (PCR) at Week 48 in Total Golodirsen Group
Percent change from baseline in Exon 53 skipping (in muscle biopsy samples) was determined by reverse transcription polymerase chain reaction in total golodirsen group.
Time frame: Baseline, Week 48
Part 2a: Percent Change From Baseline in Dystrophin Positive Fibers Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group
Percent change from baseline in dystrophin positive fibers (in muscle biopsy samples) were determined by Immunohistochemistry at Week 48 in total golodirsen group.
Time frame: Baseline, Week 48
The study was conducted at 5 sites in the France, Italy, United Kingdom and United States from 13 January 2015 to 25 March 2019.
| Milestone | Part 1: Placebo | Part 1: Golodirsen | Part 2a: Total Golodirsen Group | Part 2b: Untreated Group (Natural History of Non-exon 53) |
|---|---|---|---|---|
| Started | 4 | 8 | 0 | 0 |
| Received 4 mg/kg | 0 | 8 | 0 | 0 |
| Received 10 mg/kg | 0 | 8 | 0 | 0 |
| Received 20 mg/kg | 0 | 8 | 0 | 0 |
| Received 30 mg/kg | 0 | 8 | 0 | 0 |
| Completed | 4 | 8 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Placebo | Part 1: Golodirsen | Part 2a: Total Golodirsen Group | Part 2b: Untreated Group (Natural History of Non-exon 53) |
|---|---|---|---|---|
| Started | 0 | 0 | 25 | 14 |
| Completed | 0 | 0 | 23 | 6 |
| Not completed | 0 | 0 | 2 | 8 |
| Withdrew: Enrollment in other therapeutic study | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 4 |
| Withdrew: Personal reasons | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
Adverse event (AE) was any untoward medical occurrence in a clinical trial participant, which does not necessarily have a causal relationship with the investigational drug. A Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; Required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs that were reported or worsened on or after the start of study drug dosing through 12 weeks. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | Part 1: Placebo | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|---|
| Participants with TEAE | 4 | 5 | 5 | 3 | 6 |
| Participants with Serious TEAE | 0 | 0 | 0 | 0 | 0 |
| Participants with TEAEs leading to discontinuation | 0 | 0 | 0 | 0 | 0 |
Laboratory parameters included hematology, serum chemistry (SC), urinalysis and coagulation. Number of participants with at least one potentially clinically significant abnormal finding were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potentially clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
| Participants | Part 1: Placebo | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|---|
| Hepatic Chemistry | 0 | 0 | 0 | 0 | 0 |
| Renal Chemistry | 0 | 0 | 0 | 0 | 0 |
| Hematology | 2 | 0 | 1 | 0 | 0 |
| Coagulation | 0 | 0 | 0 | 0 | 0 |
| Urinalysis | 0 | 0 | 0 | 0 | 0 |
Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potential clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
| Participants | Part 1: Placebo | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|---|
| Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs | 1 | 3 | 1 | 1 | 4 |
Physical examinations were performed by the Investigator, or qualified study staff. A full physical examination included a review of general appearance, head, eyes, ears, nose and throat, heart, lungs, abdomen, extremities, skin, lymph nodes, musculoskeletal, and neurological systems. Number of participants with potentially clinically significant abnormalities in physical examinations were reported. Potentially clinically significant abnormalities in physical examinations were based on Investigator's discretion.
| Participants | Part 1: Placebo | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|---|
| Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Physical Examinations | 0 | 0 | 2 | 0 | 3 |
Twelve-lead ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECG reported as TEAEs presented here. The Investigator determined whether abnormal assessment results were potentially clinically significant or not.
| Participants | Part 1: Placebo | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|---|
| Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs | 0 | 1 | 0 | 0 | 0 |
Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. Cardiac function events included cardiomegaly, tachycardia, and dyspnoea. The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECHO were reported.
| Participants | Part 1: Placebo | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|---|
| Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO) | 0 | 0 | 0 | 0 | 3 |
6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 144 in total golodirsen group was reported.
| meters | Part 2a: Total Golodirsen Group |
|---|---|
| Part 2a: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Total Golodirsen Group | -99.0 ± 123.75 |
6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 144 in untreated group (non-exon 53 amenable participants) was calculated.
| Meters | Part 2b: Untreated Group (Natural History of Non-exon 53) |
|---|---|
| Part 2b: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Untreated Group (Non-exon 53 Amenable Participants) | -160.8 ± 162.41 |
Change from baseline in dystrophin protein levels (in muscle biopsy samples) was determined by Western blot in total golodirsen group.
| Percent normal dystrophin protein level | Part 2a: Total Golodirsen Group |
|---|---|
| Part 2a: Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 48 in Total Golodirsen Group | 0.924 ± 1.0129 |
Maximum Concentration (Cmax) of golodirsen in plasma was evaluated.
| nanogram per milliliter (ng/mL) | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|
| Part 1: Maximum Plasma Concentration (Cmax) of Golodirsen | 7840 ± 45.7 | 17000 ± 40.9 | 39700 ± 71.8 | 53300 ± 37.9 |
Time to reach maximum plasma concentration (Tmax) of golodirsen was evaluated.
| hour | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|
| Part 1: Time to Reach Maximum Plasma Concentration (Tmax) of Golodirsen | 1.11 (0.77 to 1.67) | 1.09 (0.12 to 1.62) | 1.12 (0.80 to 1.58) | 1.12 (0.68 to 1.50) |
Area under the concentration-time curve from time zero extrapolated to the infinity was evaluated.
| hr*ng/mL | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|
| Part 1: Area Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Golodirsen in Plasma | 11800 ± 35.5 | 26400 ± 42.7 | 62300 ± 52.6 | 90800 ± 33.4 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution at steady state of golodirsen was evaluated.
| Liter per kilogram (L/kg) | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|
| Part 1: Apparent Volume of Distribution at Steady State (Vss) of Golodirsen | 0.670 ± 38.6 | 0.767 ± 43.4 | 0.576 ± 84.5 | 0.668 ± 32.3 |
T1/2 is the time measured for the plasma concentration of drug to decrease by one half. T1/2 of golodirsen was evaluated.
| hour | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|
| Part 1: Elimination Half-life (T1/2) of Golodirsen | 2.36 ± 0.581 | 3.63 ± 2.04 | 3.27 ± 0.897 | 3.42 ± 0.628 |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| Liters per hour per kilogram (L/h/kg) | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|
| Part 1: Total Clearance (CL) of Golodirsen | 0.381 ± 36.0 | 0.405 ± 46.2 | 0.338 ± 52.2 | 0.346 ± 34.3 |
MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method. Mean residence time of golodirsen was evaluated.
| hour | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|
| Part 1: Mean Residence Time (MRT) of Golodirsen | 1.79 ± 0.325 | 1.92 ± 0.338 | 1.77 ± 0.495 | 1.95 ± 0.312 |
Renal clearance was calculated using the partial AUC0-24 from the non-compartmental analysis in plasma and AE0-24. AUC0-24 was defined as area under the plasma concentration-time curve, from time 0 to 24 hours after completion of dosing. AE0-24 was defined as total cumulative amount excreted from 0 to 24 hours. Summarized data of all urine collection intervals are reported.
| L/h/kg | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) |
|---|---|---|---|---|
| Part 1: Renal Clearance (CLR) of Golodirsen | 0.345 ± 31.9 | 0.370 ± 50.6 | 0.355 ± 42.1 | 0.374 ± 26.8 |
FVC was the total amount of air exhaled during the forced expiratory volume test that was measured during spirometry and the most important measurement of lung function. This test required participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which was used to dilate participant bronchial (breathing) tubes. Percent of predicted FVC = (observed value)/ (predicted value) \* 100%.
| Percent change | Part 2a: Total Golodirsen Group |
|---|---|
| Part 2a: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Total Golodirsen Group | -8.382 ± 29.4566 |
FVC was the total amount of air exhaled during the forced expiratory volume test that was measured during spirometry and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which was used to dilate participant bronchial (breathing) tubes. Percent of predicted FVC = (observed value)/ (predicted value) \* 100%.
| Percent change | Part 2b: Untreated Group (Natural History of Non-exon 53) |
|---|---|
| Part 2b: Percent Change From Baseline in Forced Vital Capacity Predicted (FVC%p) at Week144 in Untreated Group (Non-exon 53 Amenable Participants) | -6.739 ± 17.5278 |
Change from baseline in dystrophin Intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry in total golodirsen group.
| Percent dystrophin positive fibers | Part 2a: Total Golodirsen Group |
|---|---|
| Part 2a: Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group | 0.023 ± 0.0243 |
Percent change from baseline in Exon 53 skipping (in muscle biopsy samples) was determined by reverse transcription polymerase chain reaction in total golodirsen group.
| Percent change | Part 2a: Total Golodirsen Group |
|---|---|
| Part 2a: Percent Change From Baseline in Exon 53 Skipping Determined by Reverse Transcription Polymerase Chain Reaction (PCR) at Week 48 in Total Golodirsen Group | 16.363 ± 10.6223 |
Percent change from baseline in dystrophin positive fibers (in muscle biopsy samples) were determined by Immunohistochemistry at Week 48 in total golodirsen group.
| Percent change | Part 2a: Total Golodirsen Group |
|---|---|
| Part 2a: Percent Change From Baseline in Dystrophin Positive Fibers Determined by Immunohistochemistry (IHC) at Week 48 in Total Golodirsen Group | 12.508 ± 14.6012 |
Collected over From start of study drug administration up to 189 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Part 1: Golodirsen (4 mg/kg) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Part 1: Golodirsen (10 mg/kg) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Part 1: Golodirsen (20 mg/kg) | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Part 1: Golodirsen (30 mg/kg) | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Part 2a: Total Golodirsen Group | 0/25 (0%) | 4/25 (16%) | 25/25 (100%) |
| Part 2b: Untreated Group (Natural History of Non-exon 53) | 0/14 (0%) | 2/14 (14.3%) | 10/14 (71.4%) |
| Event | Part 1: Placebo | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) | Part 2a: Total Golodirsen Group | Part 2b: Untreated Group (Natural History of Non-exon 53) |
|---|---|---|---|---|---|---|---|
| Tooth development disorderGastrointestinal disorders | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/25 | 1/14 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/25 | 1/14 |
| HaematemesisGastrointestinal disorders | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 1/25 | 0/14 |
| VomitingGastrointestinal disorders | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 1/25 | 0/14 |
| PyrexiaGeneral disorders | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 1/25 | 0/14 |
| Gastroenteritis viralInfections and infestations | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 1/25 | 0/14 |
| HypocalcaemiaMetabolism and nutrition disorders | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 1/25 | 0/14 |
| ConvulsionNervous system disorders | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 1/25 | 0/14 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 1/25 | 0/14 |
| Event | Part 1: Placebo | Part 1: Golodirsen (4 mg/kg) | Part 1: Golodirsen (10 mg/kg) | Part 1: Golodirsen (20 mg/kg) | Part 1: Golodirsen (30 mg/kg) | Part 2a: Total Golodirsen Group | Part 2b: Untreated Group (Natural History of Non-exon 53) |
|---|---|---|---|---|---|---|---|
| RhinitisInfections and infestations | 0/4 | 0/8 | 0/8 | 0/8 | 2/8 | 16/25 | 0/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/4 | 0/8 | 0/8 | 0/8 | 3/8 | 16/25 | 3/14 |
| VomitingGastrointestinal disorders | 0/4 | 0/8 | 0/8 | 1/8 | 1/8 | 15/25 | 1/14 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 1/8 | 0/8 | 0/8 | 1/8 | 14/25 | 0/14 |
| NasopharyngitisInfections and infestations | 1/4 | 1/8 | 0/8 | 0/8 | 1/8 | 13/25 | 4/14 |
| PyrexiaGeneral disorders | 1/4 | 2/8 | 1/8 | 1/8 | 4/8 | 13/25 | 1/14 |
| Platelet count increasedInvestigations | 2/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/25 | 0/14 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/8 | 0/8 | 0/8 | 2/8 | 12/25 | 0/14 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/4 | 0/8 | 0/8 | 0/8 | 1/8 | 11/25 | 0/14 |
| HeadacheNervous system disorders | 0/4 | 0/8 | 0/8 | 1/8 | 3/8 | 11/25 | 0/14 |
Safety set included all randomized participants from Part 1 and all Part 2 participants amenable to exon 53 skipping who received any amount of study drug, and all untreated participants who entered Part 2.
| Age, Continuous(years) | Part 1: Placebo | Part 1: Golodirsen | Part 2a: Total Golodirsen Group | Part 2b: Untreated Group (Natural History of Non-exon 53) | Total |
|---|---|---|---|---|---|
| Part 1 | 7.0 ± 0.82 | 8.6 ± 2.07 | — | — | 8.1 ± 1.88 |
| Part 2 | — | — | 8.4 ± 2.18 | 8.5 ± 1.91 | 8.4 ± 2.06 |
| Sex: Female, Male(Participants) | Part 1: Placebo | Part 1: Golodirsen | Part 2a: Total Golodirsen Group | Part 2b: Untreated Group (Natural History of Non-exon 53) | Total |
|---|---|---|---|---|---|
| Part 1 — Female | 0 | 0 | — | — | 0 |
| Part 1 — Male | 4 | 8 | — | — | 12 |
| Part 2 — Female | — | — | 0 | 0 | 0 |
| Part 2 — Male | — | — | 25 | 14 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Placebo | Part 1: Golodirsen | Part 2a: Total Golodirsen Group | Part 2b: Untreated Group (Natural History of Non-exon 53) | Total |
|---|---|---|---|---|---|
| Part 1 — Hispanic or Latino | 1 | 1 | — | — | 2 |
| Part 1 — Not Hispanic or Latino | 1 | 4 | — | — | 5 |
| Part 1 — Unknown or Not Reported | 2 | 3 | — | — | 5 |
| Part 2 — Hispanic or Latino | — | — | 4 | 0 | 4 |
| Part 2 — Not Hispanic or Latino | — | — | 9 | 9 | 18 |
| Part 2 — Unknown or Not Reported | — | — | 12 | 5 | 17 |
| Race (NIH/OMB)(Participants) | Part 1: Placebo | Part 1: Golodirsen | Part 2a: Total Golodirsen Group | Part 2b: Untreated Group (Natural History of Non-exon 53) | Total |
|---|---|---|---|---|---|
| Part 1 — American Indian or Alaska Native | 0 | 0 | — | — | 0 |
| Part 1 — Asian | 0 | 0 | — | — | 0 |
| Part 1 — Native Hawaiian or Other Pacific Islander | 0 | 0 | — | — | 0 |
| Part 1 — Black or African American | 0 | 0 | — | — | 0 |
| Part 1 — White | 3 | 8 | — | — | 11 |
| Part 1 — More than one race | 1 | 0 | — | — | 1 |
| Part 1 — Unknown or Not Reported | 0 | 0 | — | — | 0 |
| Part 2 — American Indian or Alaska Native | — | — | 0 | 0 | 0 |
| Part 2 — Asian | — | — | 0 | 1 | 1 |
| Part 2 — Native Hawaiian or Other Pacific Islander | — | — | 0 | 0 | 0 |
| Part 2 — Black or African American | — | — | 0 | 0 | 0 |
| Part 2 — White | — | — | 23 | 11 | 34 |
| Part 2 — More than one race | — | — | 2 | 2 | 4 |
| Part 2 — Unknown or Not Reported | — | — | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2015 to primary completion in Mar 2019, 50 months.
Results were first posted in Oct 2020, 1 year 6 months after primary completion.
Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's 50 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Golodirsen
Muscular Dystrophy, Duchenne →